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Introduction
Juvenile dermatomyositis (JDM) is a multisystem vascu-
lopathic disease that affects primarily the skin and mus-
cle and is characterized by high risk of morbidity and
long-term damage. Regular patient assessment through
standardized quantitative clinical measures is important
to monitor the disease course over time and to evaluate
treatment effectiveness. However, only a few outcome
measures specifically validated for use in JDM are
available.
Objectives
To investigate the construct validity of the following
new clinical measures for JDM developed by our group:
1) JDM-Act (global disease activity); 2) MyoFun (physi-
cal function); 3) Pediatric Rheumatology Quality of Life
scale, PRQL (health related quality of life).
Methods
Construct validity was assessed by computing the corre-
lations between the new clinical measures and conven-
tional JDM outcome measures by means of the
Spearman’s correlation coefficient. Correlations were
considered good, moderate, or poor when the rs was >
0.7, 0.4-0.7, or < 0.4, respectively.
Results
A total of 107 consecutive JDM patients (44 male,
63 female) seen in 4 pediatric rheumatology centres
were included in the study. Mean disease duration was
3,1 years (IQR:1,0-5,8) and mean age at visit was 10
years (IQR:6,4-13,6). The table shows the Spearman’s
correlations of JDM-Act, MyoFun and PRQL scores
with the values of conventional measures of disease
activity and damage.
Conclusion
The new clinical measures showed good construct valid-
ity. By documenting this key measurement property, we
have shown that the new tools are valid instruments for
the assessment of children with JDM and are, therefore,
potentially applicable in both clinical and research con-
texts. Because the new measures are simpler and shorter
than most existing instruments, they may help foster the
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Table 1




-0.71 -0.72 0.86 0.31 0.26 0.59 0.66
MyoFun -0.58 -0.56 0.51 0.38 0.12 0.83 0.79
PRQL-Physical
Health
-0.52 -0.54 0.54 0.34 0.15 0.75 0.85
PRQL total score -0.47 -0.48 0.46 0.27 0.14 0.71 0.82
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